We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
-22.83%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.04B
AUM Growth
-$590M
Cap. Flow
-$271M
Cap. Flow %
-26.22%
Top 10 Hldgs %
52.21%
Holding
94
New
6
Increased
10
Reduced
22
Closed
23

Top Buys

Rank Stock Value
1
ARLZ
Aralez Pharmaceuticals Inc.
ARLZ
+$19.6M
2
NVDQ
Novadaq Technologies Inc.
NVDQ
+$18.9M
3
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
+$18.4M
4
CSII
Cardiovascular Systems, Inc.
CSII
+$14.8M
5
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$7.38M

Top Sells

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$91.5M
2
NVRO
NEVRO CORP.
NVRO
+$31.5M
3
EBS icon
Emergent Biosolutions
EBS
+$26.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$22.9M
5
ATRC icon
AtriCure
ATRC
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 70.61%
2 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$113M 10.92%
6,823,377
-1,307,933
-16% -$22.9M
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$81.2B
$111M 10.68%
1,000,000
-150,000
-13% -$15.5M
NVDQ
3
DELISTED
Novadaq Technologies Inc.
NVDQ
$60.6M 5.85%
5,465,216
+1,782,203
+48% +$18.9M
AVDL
4
DELISTED
Avadel Pharmaceuticals
AVDL
$48.5M 4.69%
4,394,464
– –
TVTX icon
5
Travere Therapeutics
TVTX
$5.16B
$40.4M 3.9%
2,959,790
– –
PGNX
6
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$39M 3.77%
8,951,169
– –
NVRO
7
DELISTED
NEVRO CORP.
NVRO
$37.6M 3.63%
667,907
-533,573
-44% -$31.5M
RPTP
8
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$32.2M 3.11%
7,000,000
+4,587,005
+190% +$18.4M
ANGO icon
9
AngioDynamics
ANGO
$567M
$30.7M 2.97%
2,498,527
– –
HRTX icon
10
Heron Therapeutics
HRTX
$90.9M
$27.8M 2.69%
1,465,475
-766,526
-34% -$15.1M
HZNP
11
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$24.9M 2.4%
1,500,000
+1,000,000
+200% +$17.5M
LJPC
12
DELISTED
La Jolla Pharmaceutical Company
LJPC
$24.4M 2.35%
1,165,373
– –
ANAC
13
CALL
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$21.4M 2.06%
+400,000
New +$29.5M
PETX
14
DELISTED
Aratana Therapeutics, Inc.
PETX
$18.9M 1.83%
3,428,865
– –
NVRO
15
CALL
DELISTED
NEVRO CORP.
NVRO
$16.9M 1.63%
+300,000
New +$17.7M
BDSI
16
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$16.8M 1.62%
5,188,794
+500,000
+11% +$1.85M
RXDX
17
DELISTED
Ignyta, Inc.
RXDX
$15.3M 1.48%
2,256,546
– –
ADXS
18
DELISTED
Advaxis Inc
ADXS
$15.3M 1.47%
112,701
– –
CSII
19
DELISTED
Cardiovascular Systems, Inc.
CSII
$15.2M 1.46%
+1,462,663
New +$14.8M
AEGR
20
DELISTED
Aegerion Pharmaceuticals
AEGR
$14.8M 1.43%
4,010,291
+500,000
+14% +$3.1M
SPNE
21
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$14.6M 1.41%
1,000,007
– –
ARLZ
22
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$13.5M 1.3%
+3,800,000
New +$19.6M
GNMX
23
DELISTED
Aevi Genomic Medicine Inc
GNMX
$13.4M 1.29%
3,045,306
– –
ATRS
24
DELISTED
Antares Pharma, Inc.
ATRS
$13.1M 1.27%
15,085,393
+3,610,393
+31% +$3.49M
SCTL
25
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$12.3M 1.19%
2,296,996
– –
1
2 3 4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Broadfin Capital held 94 positions worth $1.04B, down 36% from $1.63B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Broadfin Capital withdrew a net $271M in Q1 2016, closing 23 positions and reducing 22 holdings. Its most notable exit was Bausch Health, an estimated $91.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 79% a quarter earlier, followed by Technology.

Against the trend, Broadfin Capital opened a new position in Aralez Pharmaceuticals Inc. worth $13.5M.

  • Broadfin Capital's largest Q1 2016 buy was Aralez Pharmaceuticals Inc.: 3,800,000 shares worth $13.5M.
  • Broadfin Capital added most to Novadaq Technologies Inc. in Q1 2016, an estimated $18.9M increase.
  • Broadfin Capital's biggest Q1 2016 reduction was NEVRO CORP., cutting an estimated $31.5M.
  • Broadfin Capital fully exited Bausch Health in Q1 2016, selling an estimated $91.5M.
  • Broadfin Capital's ten largest holdings make up 52% of its $1.04B portfolio in Q1 2016.
  • Broadfin Capital opened 6 new positions and closed 23 in Q1 2016.
  • Broadfin Capital's portfolio value fell 36% quarter-over-quarter to $1.04B.

Based on Broadfin Capital's 13F filing for Q1 2016, filed 16 May 2016.